Clinical trials: Hip Replacement
Arthroplasty, Replacement, Hip
Restoration® Modular Revision Hip System Post Market Study
The purpose of this study is to demonstrate survivorship of the femoral stem at 5 years.
- Trial name
- NCT00962013
- Testing
- Restoration® Modular Revision Hip System
- Where
- 13 sites in United States
- Volunteers
- 137 people
- Sponsor
- Stryker Orthopaedics
Hip Replacement
Surgical Adhesive Drapes for Prevention and Healing of Wound Infections After Total Hip Arthroplasty
The purpose of this study is to support the rational use of iodophor-impregnated surgical adhesive drapes for preventing wound infections after total hip arthroplasty.
- Trial name
- NCT02707302
- Testing
- Iodophor-impregnated adhesive drapes group, Iodophor-free adhesive drapes group
- Volunteers
- 120 people
- Sponsor
- Third Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Osteoarthritis(Primary)
A Randomised Multi-centre Study to Compare the Short-term Outcomes of Minimally Invasive and Conventional Surgery in Primary Total Hip Replacement
The purpose of this study is to compare the short-term outcomes of two surgical techniques, minimally invasive and conventional, when used in the treatment of patients with hip joint disease requiring a total hip replacement.
- Trial name
- NCT00208416
- Testing
- DePuy MI System, Conventional surgical technique
- Where
- 2 sites in United Kingdom
- Volunteers
- 58 people
- Sponsor
- DePuy International
Non-inflammatory Joint Disease, Osteoarthritis
Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System
This study is being conducted to gather medium and long-term information regarding the performance and safety of the commercially available DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System.
- Conditions
- Non-inflammatory Joint Disease, Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia
- Trial name
- NCT00546598
- Testing
- Total hip replacement/arthroplasty
- Where
- 6 sites in United States
- Volunteers
- 106 people
- Sponsor
- DePuy Orthopaedics
Arthroplasty, Replacement, Hip
ABC/Trident® Ceramic Post Approval Study
The purpose of the Post Approval Study of the ABC and Trident® systems is to continue to demonstrate the safety and efficacy of the alumina-on-alumina bearing surfaces combined with the appropriate shell in a cementless…
- Trial name
- NCT00960206
- Testing
- Trident® Ceramic Insert/Trident® AD HA Acetabular Shell, Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell, OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
- Where
- 6 sites in United States
- Volunteers
- 413 people
- Sponsor
- Stryker Orthopaedics
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- RECORD 2 (NCT00332020)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 126 sites in United States, Australia and 21 more
- Volunteers
- 2,457 people
- Sponsor
- Bayer